Alopecia Universalis With IL-12-RB1 and STAT4 Mutations Effectively Treated With Upadacitinib

August 2024 in “ JAAD Case Reports ”

Emily R. Gordon, Luke Horton, Natasha Atanaskova Mesinkovska

alopecia universalis IL-12-RB1 STAT4 upadacitinib Janus kinase inhibitor JAK-STAT pathway genetic testing JAK inhibitor

Studysummary This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on jaadcasereports.org →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review

14 citations , April 2023 in “Acta Dermato Venereologica”

Upadacitinib effectively treated severe hair loss in a child.

Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

research Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib: A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

9 citations , January 2023 in “Dermatology and therapy”

This case report describes a 14-year-old girl with alopecia universalis and mild atopic dermatitis who achieved complete hair regrowth and eczema resolution after three months of treatment with the JAK1 inhibitor upadacitinib.

Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

research Impact of Pediatric Alopecia Areata on Quality of Life of Patients and Their Family Members: A Nationwide Multicenter Questionnaire Study

17 citations , January 2022 in “Annals of Dermatology”

In this study, the severity of pediatric alopecia areata was found to decrease the quality of life for both patients and their families while increasing the overall burden.

An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature

research An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature

11 citations , November 2019 in “Clinical Case Reports”

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

research Tofacitinib Therapy for Children with Severe Alopecia Areata

39 citations , January 2019 in “Journal of the American Academy of Dermatology”

In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.

research Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children

40 citations , September 2018 in “Journal of the American Academy of Dermatology”

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.